Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease: cross-sectional findings from the AGES-Reykjavik Study

Thomas T. van Sloten, MD, PhD; Gary F. Mitchell, MD; Sigurdur Sigurdsson, MSc; Mark A. van Buchem, MD, PhD; Palmi V. Jonsson, MD; Melissa E. Garcia, MPH; Tamara B. Harris, MD, MS; Ronald M.A. Henry, MD, PhD; Andrew S. Levey, MD; Coen D.A. Stehouwer, MD, PhD; Vilmundur Gudnason, MD, PhD; Lenore J. Launer, PhD

Introduction

Depression and depressive symptoms are frequently encountered in older individuals.1 Depressive symptoms in older populations, even in the absence of a clinical diagnosis of depression, are associated with a 1.5- to 2-fold higher mortality risk.2,3 The pathobiology of late-life depression is incompletely understood, but it has been suggested that arterial stiffness is involved.4 Arterial stiffness impairs the cushioning function of large arteries, reduces wave reflection and increases pressure and flow pulsatility, which transmits distally and damages the microcirculation.5–7 Microvascular damage leads to impaired vasoreactivity and cerebral hypoperfusion and can manifest itself as cerebral small vessel disease, including white matter hyperintensities, subcortical infarcts, cerebral microbleeds, Virchow–Robin spaces and cerebral atrophy.5–8 Cerebral small vessel disease, in turn, may predispose to depression via disruption of frontal and subcortical structures involved in mood regulation.9,10 In accordance, previous studies4,12–17 have shown an association between arterial stiffness and cerebral small vessel disease. The studies were conducted in the general population6,12–14,17 (sample sizes ranged from 30313 to 1460 individuals14), or in selected clinical populations (e.g., individuals with diabetes [n = 178]15 or hypertension [n = 167]16). Most of these studies, but not all,13 were cross-sectional by design. Furthermore, recent longitudinal data of the Age, Gene/Environment Susceptibility (AGES)-Reykjavik study (n = 1949)18 and the Three City (3C) study (n = 1214)19 have shown that markers of cerebral small vessel disease are associated with incident depressive symptoms.

However, only 3 studies4,12,17 have evaluated the association between arterial stiffness and depression, and these studies yielded inconsistent results. The Rotterdam Study (n = 3704)4 and a small case–control study (n = 46),20 which both included older individuals (mean age of both study samples 72 yr),

Background: Arterial stiffness may contribute to depression via cerebral microvascular damage, but evidence for this is scarce. We therefore investigated whether arterial stiffness is associated with depressive symptoms and whether cerebral small vessel disease contributes to this association. Methods: This cross-sectional study included a subset of participants from the AGES-Reykjavik study second examination round, which was conducted from 2007 to 2011. Arterial stiffness (carotid–femoral pulse wave velocity [CFPWV]), depressive symptoms (15-item geriatric depression scale [GDS-15]) and cerebral small vessel disease (MRI) were determined. Manifestations of cerebral small vessel disease included higher white matter hyperintensity volume, subcortical infarcts, cerebral microbleeds, Virchow–Robin spaces and lower total brain parenchyma volume. Results: We included 2058 participants (mean age 79.6 yr; 59.0% women) in our analyses. Higher CFPWV was associated with a higher GDS-15 score, after adjustment for potential confounders (β 0.096, 95% confidence interval [CI] 0.005–0.187). Additional adjustment for white matter hyperintensity volume or subcortical infarcts attenuated the association between CFPWV and the GDS-15 score, which became nonsignificant (p > 0.05). Formal mediation tests showed that the attenuating effects of white matter hyperintensity volume and subcortical infarcts were statistically significant. Virchow–Robin spaces, cerebral microbleeds and cerebral atrophy did not explain the association between CFPWV and depressive symptoms. Limitations: Our study was limited by its cross-sectional design, which precludes any conclusions about causal mediation. Depressive symptoms were assessed by a self-report questionnaire. Conclusion: Greater arterial stiffness is associated with more depressive symptoms; this association is partly accounted for by white matter hyperintensity volume and subcortical infarcts. This study supports the hypothesis that arterial stiffness leads to depression in part via cerebral small vessel disease.

Correspondence to: L.J. Launer, Intramural Research Program, National Institute on Aging, Bethesda, MD; LaunerL@nia.nih.gov

Submitted Nov. 8, 2014; Revised Apr. 22, 2015; Revised June 14, 2015; Accepted June 24, 2015; Early-released Oct. 20, 2015

DOI: 10.1503/jpn.140334

© 2016 Joule Inc. or its licensors
showed an association between greater arterial stiffness and presence of depression. In contrast, the Netherlands Study of Depression and Anxiety (NESDA; \( n = 618 \)) did not find an association between arterial stiffness and depression.\(^2\) However, the NESDA included a relatively young sample (mean age 47 yr). The contribution of arterial stiffness and cerebral small vessel disease to depression may be more important in older people. In addition, the foregoing studies did not evaluate whether the presence of cerebral small vessel disease contributes to the association (if any) between arterial stiffness and depression.

In view of the above findings, we investigated in a large population-based cohort of older men and women whether arterial stiffness was associated with depressive symptoms and whether any such association was explained by manifestations of cerebral small vessel disease, including white matter hyperintensities, subcortical infarcts, Virchow–Robin spaces, cerebral microbleeds and cerebral atrophy.

**Methods**

**AGES-Reykjavik Study**

For the present study, we used cross-sectional data from the AGES-Reykjavik Study second examination, which took place from 2007 to 2011. The AGES-Reykjavik Study is a population-based cohort study originating from the Reykjavik Study, as described elsewhere.\(^2\)\(^2\)\(^2\) It aimed to investigate genetic and environmental factors and biological mechanisms leading to major clinical and subclinical disorders in old age, including those prevalent in neurocognitive, vascular, musculoskeletal, body compositional and metabolic symptoms. The AGES-Reykjavik Study was approved by the National Bioethics Committee in Iceland (approval number: VSN-00–063), and by the National Institute on Aging Intramural Institutional Review Board. All participants gave written informed consent. Briefly, from 2002 to 2006, 5764 surviving participants in the Reykjavik Study were examined. From 2007 to 2011 there was a follow-up examination of all surviving participants who agreed to participate (\( n = 3316 \)). Reasons for not attending the follow-up examination included death (\( n = 1039 \)), refusal (\( n = 1198 \)) and loss to follow-up (\( n = 211 \)).

**Arterial stiffness**

We assessed arterial stiffness by determining carotid–femoral pulse wave velocity (CFPWV), as previously described.\(^4\) Briefly, after 15–20 min in a supine posture, we measured brachial blood pressure and arterial tonometry with an electronic tonometer (Cardiovascular Engineering, Inc.).\(^4\) Transit distance from the carotid to femoral arteries was assessed with body surface measurements from the suprasternal notch to the carotid and femoral pulse recording sites. We computed CFPWV as the pulse wave transit distance divided by the transit time of the pulse wave from the carotid to femoral arteries, with adjustment for parallel transmission of the arterial pulse wave in the brachiocephalic artery and aortic arch.\(^4\) Higher CFPWV indicates greater arterial stiffness.

**Depressive symptoms**

We assessed depressive symptoms using the 15-item Geriatric Depression Scale (GDS-15; score range 0–15).\(^2\)\(^3\) Higher GDS-15 scores indicate the presence of more depressive symptoms. The GDS-15 score can be used as a continuous as well as a dichotomous measure.\(^2\) In the present study, we used the continuous variable as the primary outcome, because this offers the highest power to detect associations. In secondary analyses we also evaluated associations with dichotomous measures of depressive symptoms, defined as a dichotomous GDS-15 score of 6 or higher\(^2\)\(^3\) and/or use of antidepressant medication (tricyclic antidepressants, selective serotonin reuptake inhibitors, other non-tricyclics and monoamine oxidase inhibitors), as assessed based on medication bottles brought to the clinic. In addition, the association with apathy was evaluated. The following 3 items of the GDS-15 score are related to apathy: 1) “Have you dropped many of your activities and interests?”; 2) “Do you prefer to stay at home, rather than going out and doing new things?”; and 3) “Do you feel full of energy?”\(^2\)\(^4\)\(^2\)\(^5\) As described previously,\(^2\)\(^4\)\(^2\)\(^5\) we distinguished an apathy subscale that included all apathy items (range 0–3; GDS-3A). Presence of apathy was defined as a GDS-3A score of 2 or 3 versus no apathy (score of 0 or 1).

**Brain MRI measures**

**Image acquisition**

All eligible participants were offered a high-resolution brain MRI acquired on the same study-dedicated 1.5 T Signa Twinspeed scanner (General Electric Medical Systems). The same imaging protocol was used as in the first examination of the AGES-Reykjavik Study, which is described elsewhere,\(^2\)\(^2\)\(^6\)\(^2\)\(^7\) and included the following sequences: 3-dimensional spoiled-gradient recalled \( T_1 \)-weighted, proton density/\( T_2 \)-weighted fast spin-echo, fluid-attenuated inversion recovery (FLAIR) and \( T_2 \)-weighted gradient-echo type echo-planar image (GRE-EPI). All images were acquired to give full brain coverage, with slices angled parallel to the anterior commissure-posterior commissure line in order to give reproducible image views in the oblique-axial plane.

**Image analysis**

We evaluated several manifestations of cerebral small vessel disease. White matter hyperintensity volume (WMHV) and total brain parenchyma volume (an indicator of cerebral atrophy) were computed automatically with a previously described image analysis pipeline\(^2\)\(^9\) and were calculated as the percentage of total intracranial volume (ICV). We considered lower total brain parenchyma volume to be a manifestation of cerebral small vessel disease, as cerebral small vessel disease may contribute to generalized loss of brain parenchyma via, among others, microinfarcts\(^2\)\(^9\) and loss of white matter integrity.\(^3\)\(^0\) Subcortical infarcts were evaluated as described previously\(^2\)\(^6\) and defined as a brain parenchyma defect with a minimum diameter of 4 mm, not extending into the cortex, with a signal intensity equal to cerebrospinal fluid on all pulse sequences (i.e., \( T_1 \)-weighted, proton density-weighted and FLAIR) and surrounded by an area of high signal intensity on
FLAIR images. Parenchymal defects in the subcortical area with evidence of hemosiderin on the $T_2^*$-weighted GRE-EPI scan were labelled as resorbed hematomas and were excluded from the definition of subcortical infarcts. In addition, Virchow–Robin spaces were evaluated separately and defined as defects in the subcortical area without a rim or area of high signal intensity on FLAIR and without evidence of hemosiderin on the $T_2^*$-weighted GRE-EPI scan. We considered the presence of Virchow–Robin spaces to be a manifestation of cerebral small vessel disease, as they are associated with endothelial dysfunction, which may play a role in the pathogenesis of cerebral small vessel disease. Cerebral microbleeds were defined as a focal area of signal void within the brain parenchyma visible on $T_2^*$-weighted GRE-EPI scans and were identified as described previously.

Confounding variables

Education (categorized into primary, secondary and college/university education) was measured at baseline. All other confounding variables were measured during the second examination of the AGES-Reykjavik Study. Smoking history (categorized into none, former and current smoker) was assessed using a questionnaire. Use of antihypertensive medication was assessed using a questionnaire and by assessing medication bottles brought to the clinic. We evaluated brachial artery mean arterial pressure and heart rate during the arterial stiffness measurements by using a computer-controlled manometer and an electrocardiogram, respectively. Gait speed, a measure of physical performance, was also administered. Digit Symbol Substitution Test (DSST), a measure of cognitive function, was also administered.

Statistical analysis

We performed our statistical analyses using PASW statistics version 21. We inverse-transformed CFPWV to reduce heteroscedasticity and multiplied it by –1000 to restore directionality and to convert the units to milliseconds per metre. In addition, CFPWV was entered as a sex-specific quartile, a measure of atherosclerosis, was based on computed tomography scan. The Digit Symbol Substitution Test (DSST), a measure of cognitive function, was also administered.

We found no such interaction ($p = 0.57$) and, therefore, all results are presented for men and women combined.

Results

Of the 3316 participants of the second examination of the AGES-Reykjavik Study, 648 had missing brain MRI data, 419 had missing data on arterial tonometry and 77 had missing data on depressive symptoms. Reasons for missing MRI data were contraindications ($n = 272$), refusal/nonattendance ($n = 337$) or technical reasons (no qualitatively acceptable MRI data available for all necessary sequences; $n = 39$). Missing data on tonometry was due to logistical or technical reasons. Of the remaining 2172 participants, we excluded those with a diagnosis of dementia (all subtypes; $n = 114$), which was diagnosed according to international guidelines by a panel that included a geriatrician, a neurologist, a neuropsychologist and a neuroradiologist, as described elsewhere. Excluded participants were more likely to be older (81.2 yr v. 76.6 yr), less educated (primary school or less: 23.6% v. 18.9%) and to have a higher body mass index (BMI; 27.3 v. 26.5) and to have unstandardized regression coefficients with corresponding 95% confidence intervals (CI).

We used mediation analysis to test the hypothesis that manifestations of cerebral small vessel disease (that is, higher WMHV, presence of subcortical infarcts, Virchow–Robin spaces, cerebral microbleeds and lower total brain parenchyma volume) are on the potential causal pathway of the association between arterial stiffness and depressive symptoms. The model quantifies the degree to which a variable statistically moderates the association of a dependent variable with an independent variable. We used bootstrapping (10 000 samples) to calculate bias-corrected 95% CIs of the explained effects using the PROCESS statistical package for PASW statistics. The magnitude of the explained effect was calculated as a percentage of the total direct effect.

We performed the following secondary analyses. Logistic analysis was performed to evaluate the association between CFPWV and a dichotomous measure of depressive symptoms. It has been suggested that cerebral small vessel disease may be associated with, in particular, apathy-related or motivation-related symptoms of depression, but not with mood-related symptoms. Therefore, we performed logistic regression analyses to evaluate the association between CFPWV and individual apathy items of the GDS-15 score as the outcome. To minimize the potential confounding effect of stroke, we repeated the analyses after excluding individuals with a clinical diagnosis of stroke. In addition, it has been suggested that deep or infratentorial cerebral microbleeds (i.e., microbleeds located in the basal ganglia, thalamus, brainstem and cerebellum) are more closely associated with vascular disease, whereas lobar microbleeds might be more closely associated with amyloid angiopathy. Therefore, analyses were repeated with presence of deep cerebral microbleeds only, instead of the presence of any microbleed. Finally, we investigated whether the association between arterial stiffness and depressive symptoms differed by sex by adding interaction terms between arterial stiffness and sex to the fully adjusted models. We found no such interaction ($p = 0.57$) and, therefore, all results are presented for men and women combined.
Associations between arterial stiffness, depressive symptoms and cerebral small vessel disease

Higher CFPWV (per standard deviation [SD]) was significantly associated with a higher GDS-15 score (β 0.096, 95% CI 0.005–0.187, explained variance by CFPWV $R^2 = 0.003$) after adjustment for confounders but without adjustment for any of the potential mediators.

**Association between arterial stiffness and depressive symptoms**

Higher CFPWV (per SD) was significantly associated with a higher GDS-15 score (Fig. 1A). The explained effect by WMHV was significant and was 6% of the total direct effect between CFPWV and the GDS-15 score (Table 2).

Similarly, higher CFPWV was significantly associated with the presence of subcortical infarcts (Fig. 1B), and the presence of subcortical infarcts was significantly associated with a higher GDS-15 score (Fig. 1B). When we adjusted the association between CFPWV and the GDS-15 score for subcortical infarcts, the association was attenuated and was no longer statistically significant (Fig. 1B). The effect of subcortical infarcts was significant and was 9% of the total direct effect between CFPWV and the GDS-15 score (Table 2).

When WMHV and subcortical infarcts were entered simultaneously into the mediation model, they explained 12% of the total direct effect between CFPWV and the GDS-15 score.

In contrast, Virchow–Robin spaces, cerebral microbleeds and total brain parenchyma volume did not attenuate the association between CFPWV and the GDS-15 score (Table 2 and Appendix 1, Fig. S1, available at jpn.ca). Higher CFPWV was associated with the presence of Virchow–Robin spaces and cerebral microbleeds, but these lesions were not associated with depressive symptoms. In addition, lower total brain parenchyma volume was significantly associated with more depressive symptoms, but CFPWV was not associated with lower total brain parenchyma volume.

**Secondary analyses**

We found that CFPWV was not significantly associated with a dichotomous measure of depressive symptoms (i.e., GDS-15 score ≥6) or use of antidepressant medication ($n = 336$) (odds ratio [OR] 1.10, 95% CI 0.96–1.26). In addition, CFPWV was not significantly associated with a presence of depressive symptoms, defined as a GDS-15 score of 6 or higher, irrespective of the use of antidepressant medication ($n = 109$) (OR 1.02, 95% CI 0.81–1.29). We found that CFPWV was not associated with apathy (i.e., GDS-3A score of 2 or 3) after adjustment for all potential confounders (OR 1.07, 95% CI 0.96–1.26). After the exclusion of individuals with stroke ($n = 223$), the explained effects by WMHV and subcortical infarcts did not materially change (Appendix 1, Table S1). Finally, when we repeated the analyses with the presence of deep or cerebral microbleeds instead of the presence of any microbleed, results did not materially change (data not shown).

**Discussion**

We evaluated whether arterial stiffness is associated with depressive symptoms and whether any such association can be explained by cerebral small vessel disease. We had 2 main findings. First, arterial stiffness, as determined by CFPWV, was independently associated with a higher level of depressive symptoms. Second, this association was explained in part (12%) by WMHV and subcortical infarcts, but not by Virchow–Robin spaces, cerebral microbleeds and cerebral atrophy.

These data are consistent with the hypothesis that arterial stiffness increases the risk of depressive symptoms in part via...
cerebral microvascular damage. Arterial stiffness may cause microvascular damage via an increased pulsatile load on the microcirculation.36,37 This increased load causes direct microvascular damage and induces a microvascular remodelling response. Microvascular remodelling initially serves to limit the penetration of the pulsatile pressure load into the microcirculatory system by raising vascular resistance. Yet, this protective response may ultimately become unfavourable, leading to impaired vasoreactivity, cerebral hypoperfusion and microvascular ischemia.7,34 Ischemia may damage frontal and subcortical structures or their connecting pathways involved in mood regulation and, hence, may lead to depression.7,10,11

Previous studies have shown associations of CFPWV or local carotid stiffness with various manifestations of cerebral small vessel disease, including WMHV6,12,17 and subcortical or lacunar infarcts.6,12,17 In addition, previous studies have shown an association between depression and WMHV9,38 and lacunar infarcts.38,39 Furthermore, a population-based study4 has shown that higher CFPWV and local carotid stiffness were associated with depression. The present study shows that the association between arterial stiffness and depressive symptoms is in part explained by cerebral small vessel lesions and thereby provides additional evidence consistent with the role of arterial stiffness in modulating the emergence of late-life depressive symptoms.

However, a relatively large part of the association between arterial stiffness and depressive symptoms remained unexplained after taking into account the effects of WMHV and subcortical infarcts. This remaining association may be due to vascular brain lesions not (directly) captured in the MRI scans (e.g., microinfarcts and loss of white matter integrity) that we did not incorporate into the analyses. In addition, it is possible that only a subset of the participants who scored poorly on the GDS-15 have vascular-related disease. Finally, although we adjusted for a large series of potential confounders, we cannot exclude the possibility of residual confounding.

Cerebral small vessel disease encompasses different lesions found on neuroimaging.6,8 Specific clinical consequences of each lesion type and their location are, however, not completely understood. In the present study, WMHV and subcortical infarcts explained a part of the association between arterial stiffness and depressive symptoms, whereas Virchow–Robin spaces, cerebral microbleeds and cerebral atrophy did not. Although higher CFPWV was associated with presence of Virchow–Robin spaces and cerebral microbleeds, these lesions were not associated with depressive symptoms. It is possible that Virchow–Robin spaces and cerebral microbleeds play a role early in the pathogenesis of cerebral small vessel disease,40 whereas WMHs and subcortical infarcts represent more advanced disease states. In addition, although lower brain parenchyma volume was associated with a higher level of depressive symptoms, brain parenchyma volume was not associated with CFPWV. Cerebral atrophy is strongly determined by factors other than vascular disease, particularly the process of neurodegeneration.4 This may have resulted in an underestimation of the association between CFPWV and brain parenchyma volume in the older population included in this study.

---

Fig. 1: Association between carotid–femoral pulse wave velocity (CFPWV) and the 15-item Geriatric Depression Scale (GDS-15) score and the explained effects of this association by (A) white matter hyperintensity volume and (B) subcortical infarcts. Solid lines indicate significant associations; dashed lines indicate nonsignificant associations. Associations are given as regression coefficients (β) or odds ratios (ORs), and corresponding 95% confidence intervals (CIs). The CFPWV and white matter hyperintensity volume are indicated per higher standard deviation (SD). All associations are adjusted for age, sex, education level, smoking, digit symbol substitution test score, gait speed, body mass index, diabetes, mean arterial pressure, heart rate, coronary calcium score and use of antihypertensive medication.
of depression may decrease arterial stiffness. Similarly, increased arterial stiffness is related to various cardiovascular risk factors, including obesity, dyslipidemia, hypertension, and diabetes. 

Strengths of the present study are the large population-based sample of older individuals, the comprehensive brain MRI assessment of various manifestations of cerebral small vessel disease and the extensive characterization of participants, which enabled us to adjust for a series of potential confounders.

In view of global aging and the increased prevalence of arterial stiffness with age, efforts at favourably influencing arterial stiffness may have significant public health implications for preventing vascular-related depression. Arterial stiffness may be favourably influenced by lifestyle modifications, such as weight loss, increased (habitual) physical activity and dietary modifications (e.g., low consumption of sodium). In addition, drugs, such as angiotensin receptor-2 agonists (e.g., compound 21), may lower arterial stiffness, possibly beyond any blood-pressure lowering effects. Despite these limitations, the present study provides important insights into the potential interplay between arterial stiffness and depression.

Limitations

Our study has some limitations. First, the cross-sectional design precludes any conclusions about a temporal association between arterial stiffness, cerebral small vessel disease and depressive symptoms. The evidence provided in the present study is, therefore, necessarily circumstantial. Nevertheless, it provides important support for more definitive investigations. It has been suggested that the association between depression and arterial stiffness may be bidirectional. Depressive symptoms may lead to arterial stiffness via multiple mechanisms, including inflammation, endothelial dysfunction and unfavourable lifestyle habits. Indeed, a recent small clinical trial showed that treatment of depression may decrease arterial stiffness. Further longitudinal studies are needed to clarify this issue. Furthermore, the associations between arterial stiffness, cerebral small vessel disease and depressive symptoms may reflect more direct measures of common underlying mechanisms (e.g., inflammation and oxidative stress). Second, depressive symptoms were assessed using a self-report questionnaire rather than a structured interview. Therefore, no information was available on the presence of a major depressive disorder. Third, it is possible that death or attrition between the AGES-1 and -2 studies resulted in a disproportional loss of people who were likely at high risk for depression. The associations between arterial stiffness, cerebral small vessel disease and depression found in the present study sample may be biased if associations substantively differed in people who were lost to follow-up. We consider this biased attrition unlikely, in which case the loss of the individuals reduces our power to detect existing associations. Fourth, the level and severity of depressive symptoms in this study was relatively low compared with depression rates in other European countries, but our rates are consistent with those found in a previous study conducted in Iceland. This low symptomatology may, however, have reduced the effect sizes and sensitivity to detect associations. This may explain why an association was found between arterial stiffness and a continuous depressive symptom score, but not with a dichotomous depression score. Analyses with a continuous outcome, in general, have higher statistical power than analyses with a dichotomous outcome. Finally, a relatively high number of individuals used antidepressant medication (14.3%) compared with the number of individuals with a GDS-15 score of 6 or higher (5.3%). Misclassification of the dichotomous depression score may have occurred because antidepressant medication is also prescribed for other reasons, and this may have led to an underestimation of the association between arterial stiffness and the dichotomous depression score.

Conclusion

The present study shows an association between greater arterial stiffness and more depressive symptoms in a general older population, and this association is in part explained by WMHV and subcortical infarcts.

Acknowledgements: The AGES-Reykjavík Study was funded by National Institutes of Health (NIH) (contract N01-AG-12100) and the Intramural Research Program of the National Institute on Aging, USA; the Icelandic Heart Association and the Icelandic Parliament, Iceland; and by grants from the National Institutes of Health, National Heart, Lung and Blood Institute (HL094898) and the National Institute of Diabetes and Digestive and Kidney Diseases (DK082447).

Affiliations: From the Cardiovascular Research Institute Maastricht, Limburg, Netherlands (VanSloten, Henry, Stehouwer); the School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands (VanSloten); Cardiovascular Engineering Inc, Norwood, MA, USA (Mitchell) the Icelandic Heart Association, Kopavogur, Iceland (Sigurdsson, Gudnason); the Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands (Buchem); the Department of Geriatrics, Landspitali University Hospital, Reykjavik, Iceland (Jonsson); the Faculty of Medicine, University of Iceland, Reykjavik, Iceland (Jonsson, Gudnason); the Intramural Research Program, Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA (Garcia, Harris, Launer); and the

| Table 2: Explained effects of white matter hyperintensity volume, subcortical infarcts, Virchow–Robin spaces, cerebral microbleeds and lower total brain parenchyma volume of the association between carotid-femoral pulse wave velocity and GDS-15 score* |
|-----------------|-----------|-----------|
| Manifestations of cerebral small vessel disease | β | 95% CI %† |
| White matter hyperintensity volume (per +1 SD) | 0.006 | 0.001 to 0.017 | 6% |
| Subcortical infarcts | 0.008 | 0.002 to 0.020 | 9% |
| Virchow–Robin spaces | 0.001 | −0.003 to 0.007 | 1% |
| Cerebral microbleeds | 0.001 | −0.00 to 0.007 | 1% |
| Lower total brain parenchyma volume (per –1 SD) | −0.002 | −0.009 to 0.003 | −2% |

CI = confidence interval; GDS-15: 15-item geriatric depression scale; SD = standard deviation.

*All associations adjusted for age, sex, education level, smoking, Digit Symbol Substitution Test score, gait speed, body mass index, diabetes, mean arterial pressure, heart rate, coronary calcium score and use of antihypertensive medication.

†Magnitude of the explained effect relative to the total direct effect between carotid-femoral pulse wave velocity and GDS-15 score.
Contributors: T. van Sloten, G. Mitchell, M. van Buchem, P. Jonsson, T. Harris, V. Gudnason and L. Launer designed the study. G. Mitchell, S. Sigurdsson, M. Garcia, A. Levey and V. Gudnason acquired the data, which T. van Sloten, G. Mitchell, R. Henry and C. Stehouwer analyzed. T. van Sloten and L. Launer wrote the article, which all authors reviewed and approved for publication.

References